Lv1
40 积分 2021-11-18 加入
Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial
11小时前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
14天前
已完结
Head and neck cancer
15天前
已完结
Head and neck cancer
15天前
已完结
65MO Neoadjuvant HLX11 versus European Union (EU)-sourced pertuzumab in human epidermal growth factor receptor 2 (HER2)-positive, hormone receptor (HR)-negative early or locally advanced, breast cancer (BC): A double-blind, randomised phase III equivalence study
17天前
已关闭
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
18天前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
24天前
已完结
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study
25天前
已完结
Head and Neck Cancer
28天前
已完结
Clinical application of base editing for treating β-thalassaemia
28天前
已完结
皖公网安备34019202002308
